# US 2003/0225058 A1 · Substituted azepino[4,5b]indoline derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0225058 A1
- Document ID: US20030225058A1
- Status: Published application
- Kind: A1
- Application number: 10/394,676
- Filed: 2003-03-20
- Published: 2003-12-04
- Earliest claimed: 2000-09-20
- Assignees: Pharmacia & Upjohn Company
- Inventors: Kristine E. Frank; Brad A. Acker; Michael D. Ennis; Jed F. Fisher; Jian-Min Fu; Eric Jon Jacobsen; William W. McWhorter JR.; Jeanette K. Morris; Donald Joseph Rogier
- Web page: https://patentgrep.com/patent/US20030225058A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/06: Antimigraine agents
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides compounds of Formula (I): 1 wherein R1-R4, p and q have any of the values described in the specification, as well as pharmaceutical salts thereof, and pharmaceutical compositions containing such compounds or salts. The compounds and salts are 5-HT ligands and are useful for treating diseases, disorders, and/or conditions in a mammal wherein activity of a 5-HT receptor is implicated. The compounds and salts are particularly useful for treating diseases of the central nervous system.

## Claims

### Claim 1

A compound of Formula (I):
476
wherein:
R1 is selected from the group consisting of hydrogen, C1-8alkyl, and C1-8hydrocarbylene Ar;
each R2, independently, is selected from the group consisting of C1-8alkyl, and OH;
R3 is hydrogen, C1-8alkyl, Ar, Het, R7C(═O)—, R7OC(═O)—, R5R6NC(═O)—, R7C(═S)—, R7SC(═O)—, R5R6NC(═S)—, R7SO2—, R5R6NSO2—, R7S(═O)—, R5R6NS(═O)—, RcC1-8hydrocarbylene—, or RcC1-8hydrocarbyleneC(═O)—;
each R4, independently, is selected from the group consisting of Ar, C1-8alkyl, ArO—, C1-8alkoxy, Het, halo, OH, CN, NO2, CF3, CF3O, NRaRb, N═CRaRb, R7S, C1-8hydrocarbyleneAr, and C1-8hydrocarbyleneORa;
each R5 and R6 is independently hydrogen, C1-8alkyl, C2-8alkenyl, C2-8alkynyl, haloC1-8alkyl, C3-8cycloalkenyl, Ar, or —C1-8hydrocarbyleneAr; or R5 and R6 together with the nitrogen to which they are attached form a pyrrolidino, piperidino, morpholino, or thiomorpholino ring;
each R7 is independently hydrogen, C1-8alkyl, C2-8alkenyl, C2-8alkynyl, haloC1-8alkyl, C3-8cycloalkenyl, Ar, or —C1-8hydrocarbyleneAr;
Ra and Rb, independently, are selected from the group consisting of hydrogen, C1-8alkyl, Ar, C1-3hydrocarbyleneAr, SO2Ar, SO2C1-4alkyl, (C3-8cycloalkyl)C1-8alkyl, and Het;
Rc is Ar, Het, R7CO2—, R7C(═O)—, R7OC(═O)—, R7O—, R7C1-8alkyleneO—, R7S—, R7C(═S)—, R7S(═O)—, R7S(═O)2—, R7SC(═O)—, R7C(═O)N(R7)—, R7C(═S)N(R7)—, R5R6N—, R5R6NC(═O)—, R5R6NC(═S)—, R5R6NS(═O)—, R5R6NSO2—, R7S(═O)N(R7)—, R7SO2N(R7)—, or R7N(R7)C(═O) N(R7)—;
each Ar is independently aryl or heteroaryl;
p is 0, 1, 2, 3, or 4; and
q is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
wherein any Ar of R1, R3-R7, Ra, Rb and Rc is optionally substituted with one or more (e.g. 1, 2, 3, 4, or 5) substituents independently selected from halo, CN, NO2, ORe, methylenedioxy, ethylenedioxy, CF3, OCF3, SRe, SO2Re, NRfRg, CONRfRg, CORe, Re, and C1-8hydrocarbyleneRd;
each Rd is independently hydroxy, C1-8alkoxy, cyano, SRh, or C(═O)Rh;
each Re is independently selected from the group consisting of hydrogen, C1-8alkyl, Ar, C1-3hydrocarbyleneAr, SO2Ar, SO2C1-4alkyl, (C3-8cycloalkyl)C1-8alkyl, and Het; wherein any Ar of Re is optionally substituted with one or more (e.g. 1, 2, 3, 4, or 5) substituents independently selected from halo, CN, NO2, ORd, methylenedioxy, ethylenedioxy, CF3, OCF3, SRf, SO2Rf, NRfRg, CONRfRg, CORf, Rf, and C1-8hydrocarbyleneRd;
each Rf and Rg, is independently selected from the group consisting of hydrogen, C1-8alkyl, Ar, C1-3hydrocarbyleneAr, SO2Ar, SO2C1-4alkyl, (C3-8cycloalkyl)C1-8alkyl, and Het; and
each Rh is independently hydrogen, C1-8alkyl, C2-8alkenyl, C2-8alkynyl, haloC1-8alkyl, C3-8cycloalkenyl, phenyl, or —C1-8hydrocarbylene(phenyl);
or a pharmaceutically acceptable salt thereof;
provided that when
(a) R1 is methyl; and
(b) R3 is hydrogen or —(CH2)3NR5R6, wherein R5 and R6, are each methyl;
then p and q are not each 0.

### Claim 2 (depends on 1)

The compound of claim 1 wherein R1 is hydrogen.

### Claim 3 (depends on 1)

The compound of claim 1 wherein q is 2, 3, or 4.

### Claim 4 (depends on 1)

The compound of claim 1 wherein q is 1.

### Claim 5 (depends on 1)

The compound of claim 1 wherein q is 0.

### Claim 6 (depends on 1)

The compound of claim 1 wherein R3 is hydrogen, C1-8alkyl, R5R6NC(═O)CH2—, R7SC1-8alkylene, or aryloxy(CH2)2—.

### Claim 7 (depends on 1)

The compound of claim 1, wherein R3 is hydrogen.

### Claim 8 (depends on 1)

The compound of claim 1 wherein R3 is C1-8alkyl, R5R6NC(═O)CH2— or aryloxy(CH2)2—.

### Claim 9 (depends on 1)

The compound of claim 1 wherein R3 is: 2-(3-methoxyphenoxy)ethyl, 2-(3-nitrophenoxy)ethyl, 2-(3-isopropylphenoxy)ethyl, 2-(4-pyridyloxy)ethyl, 3-phenoxypropyl, 3-(3-chlorophenoxy)propyl, 3-(4-fluorophenoxy)propyl, 2-phenoxyethyl, N-(2,3-dimethylphenyl)amino-carbonylmethyl, N-(3-methylphenyl)aminocarbonylmethyl, N-(2-fluoro-4-methylphenyl)aminocarbonylmethyl, N-mesitylaminocarbonylmethyl, N-(4-methoxyphenyl)aminocarbonylmethyl, N-(phenyl)aminocarbonylmethyl, N-(4-fluorophenyl)aminocarbonylmethyl, N-(3-nitrophenyl)aminocarbonylmethyl, N-(3-methoxyphenyl)aminocarbonylmethyl, N-(4-cyanophenyl)aminocarbonylmethyl, N-(3,5-dimethoxyphenyl)aminocarbonylmethyl, N-(2,4-dimethoxyphenyl)aminocarbonylmethyl, N-(3-chloro-4-fluorophenyl)aminocarbonylmethyl, 2-anilinoethyl, 1H-benzimidazol-2-ylmethyl, isobutoxycarbonylmethyl, carboxymethyl, N,N-dimethylaminocarbonylmethyl, aminocarbonylmethyl, 2-(phenylsulfinyl)ethyl, 2-(phenylsulfonyl)ethyl, 2-hydroxyethyl, 2-(4-chlorophenoxy)ethyl, 2-(4-fluorophenoxy)ethyl, 2-(phenylthio)ethyl, 2-aminoethyl, 2-(anilinocarbonylamino)-ethyl, 2-(benzoylamino)ethyl, 2-(phenylsulfonylamino)ethyl, N-(4-methoxyphenyl)aminocarbonylethyl, N-phenylaminocarbonylmethyl, N-(2-pyridyl)aminocarbonylmethyl, N-(4-methoxyphenyl)aminocarbonylmethyl, N-(2,3-dimethylphenyl)aminocarbonylmethyl, N-(5,6,7,8-tetrahydro-1-naphthalenyl)aminocarbonylmethyl, 3-ethylanilinocarbonylmethyl, 3-isopropylanilinocarbonylmethyl, N-(3-tert-butylphenyl)aminocarbonylmethyl, N-(1 ,3-benzothiazol-2-yl)aminocarbonylmethyl, N-(4-methyl-1 ,3-thiazol-2-yl)aminocarbonylmethyl, N-(5-methyl-1,3-thiazol-2-yl)aminocarbonylmethyl, N-(4-tert-butyl-1,3-thiazol-2-yl)aminocarbonylmethyl, N-(4-phenyl-1,3-thiazol-2-yl)aminocarbonylmethyl, 3-phenylpropyl, 2-phenoxyethyl, 2-(4-chlorophenoxy)ethyl, 2-(4-fluorophenoxy)ethyl, 2-(5,7-dibromo-8-quinolinyloxy)ethyl, 2-(8-quinolinyloxy)ethyl, 2-(5-isoquinolinyloxy)ethyl, 2-(5-quinolinyloxy)ethyl, 2-(5,6,7,8-tetrahydro-1-naphthalenyloxy)ethyl, 2-(1,3-benzodioxol-5-yloxy)ethyl, 2-(1H-indol-4-yloxy)ethyl, 2-(5,6,7,8-tetrahydro-2-naphthalenyloxy)ethyl, 2-(7-quinolinyloxy)ethyl, 2-[(5,5-dimethyl-5,6,7,8-tetrahydronaphthalen-1-yl)oxy]ethyl, N-(3-chloro-2-methylphenyl)aminocarbonylmethyl, N-[2-methyl-3-(trifluoromethyl)phenyl]aminocarbonylmethyl, N-(5,6,7,8-tetrahydronaphthalen-1-yl)aminocarbonylmethyl, N-(4-methyl-1,3-thiazol-2-yl)aminocarbonylmethyl, N-(1,3-dihydro-2-benzofuran-4-yl)aminocarbonylmethyl, N-(4-methoxyphenyl)aminocarbonylmethyl, N-(3-pyridyl)aminocarbonylmethyl, N-(4-methyl-1,3-thiazol-2-yl)amninocarbonylmethyl, or 2-(5,6,7,8-tetrahydronaphthalen-1-yloxy)ethyl.

### Claim 10 (depends on 1)

The compound of claim 1 wherein p is 1, 2, or 3.

### Claim 11 (depends on 1)

The compound of claim 1 wherein p is 0.

### Claim 12 (depends on 1)

The compound of claim 1 wherein R4 is phenyl, optionally substituted at the 2-position of the phenyl.

### Claim 13 (depends on 1)

The compound of claim 1 wherein R4 is 2-ethoxyphenyl, or 2-chliorophenyl.

### Claim 14 (depends on 1)

The compound of claim 1 wherein R4 is aryl, substituted at the 10-position of formula (I).

### Claim 15 (depends on 1)

The compound of claim 1 wherein R4 is: 5-pyrimidinyl, 3,4-dimethoxyphenyl, 3,5-difluorophenyl, 4-n-butyloxyphenyl, 4-trifluoromethoxyphenyl, 3,4-dichlorophenyl, 2-naphthyl, 4-pyridinyl, bromo, benzhydrilideneamino, amino, N-(phenylsulfonyl)amino, phenoxy, 3-(phenoxy)propyl, 3-(2-naphthyloxy)propyl, 3-(1-naphthyloxy)propyl, 3-([1,1′-biphenyl]-4-yloxy)propyl, 3-(3-methoxyphonoxy)propyl, 3-(4-methoxyphenoxy)propyl, 3-(4-chlorophenoxy)propyl, 3-(3-chlorophenoxy)propyl, 3-(2-chlorophenoxy)propyl, 3-(2,4-dichlorophenoxy)propyl, 3-(2,5-dichlorophenoxy)propyl, 3-(4-fluorophenoxy)propyl, 3-(4-methylphenoxy)propyl, 3-(4-cyanophenoxy)propyl, 3-(pyridin-2-yloxy)propyl, 3-(2-bromophenoxy)propyl, 3-(2-iodophenoxy)propyl, 3-(2-ethylphenoxy)propyl, 3-(2-isopropylphenoxy)propyl, 3-(2-cyanophenoxy)propyl, 3-(pyridin-3yloxy)propyl, 3-(3-fluorophenoxy)propyl, 3-(3-bromophenoxy)propyl, 3-(3-iodophenoxy)propyl, 3-(3-isopropylphenoxy)propyl, 3-[3-(trifluoromethyl)phenoxy]propyl, 3-[3-(trifluoromethoxy)phenoxy]propyl, 3-(3-ethylphenoxy)propyl, 3-(3-tert-butylphenoxy)propyl, 3-(pyridin-4yloxy)propyl, 3-(4-methoxyphenoxy)propyl, 3-[4-(benzyloxy)phenoxy]propyl, 3-(4-bromophenoxy)propyl, 3-(4-iodophenoxy)propyl, 3-(4-ethylphenoxy)propyl, 3-(4-tert-butylphenoxy)propyl, 3-[4′-(bromo[1,1′-biphenyl]-4-yl)oxy]propyl, 3-(2,3-difluorophenoxy)propyl, 3-(2,4-dibromophenoxy)propyl, 3-(2,4-difluorophenoxy)propyl, 3-(2-methoxy-4-methylphenoxy)propyl, 3-(4-iodo-2-methylphenoxy)propyl, 3-(2,5-difluorophenoxy)propyl, 3-(2-chloro-5-methylphenoxy)propyl, 3-(2-isopropyl-5-methylphenoxy)propyl, 3-(2,6-difluorophenoxy)propyl, 3-(2,6-dichlorophenoxy)propyl, 3-(2,6-dimethylphenoxy)propyl, 3-(2-fluoro-6-methylphenoxy)propyl, 3-hydroxypropyl, 3-(2,3,6-trimethylphenoxy)propyl, 3-(mesityloxy)propyl, 3-(2,6-dibromo-4-fluorophenoxy)propyl, 3-(4-chloro-3-fluorophenoxy)propyl, 3-(4-chloro-3-methylphenoxy)propyl, 3-(3-chloro-4-fluorophenoxy)propyl, 3-(1,3-benzodioxol-5-yloxy)propyl, 3-(3,5-dichlorophenoxy)propyl, 3-(3,5-dimethylphenoxy)propyl, 3-(3,5-dimethoxyphenoxy)propyl, 3-(5,6,7,8-tetrahydro-1-naphthalenyloxy)propyl, 3-[(2,4-dichloro-1-naphthyl)oxy]propyl, 3-[4-methoxy-1-naphthyl)oxy]propyl, 3-[4-chloro-1-naphthyl)oxy]propyl, 3-[1,6-dibromo-2-naphthyl)oxy]propyl, 3-[1-bromo-2-naphthyl)oxy]propyl, 3-(2,3,4,5,6-pentafluorophenoxy)propyl, 3-(5-isoquinolinyloxy)propyl, 2-methyl4-methoxyphenyl, 2-ethoxyphenyl, phenyl, phenoxy, 4-pyridinyl, 4-methoxyphenyl, 3,5-difluorophenyl, 3-[ 1,1′-biphenyl]-2-yloxypropyl, chloro, 2,6-difluorophenyl, bromo, 2-methylphenyl, 2-methoxyphenyl, 2-propoxyphenyl, 2-fluorophenyl, 2,4-dichlorophenyl, 3-(2,4-dibromophenoxy)propyl, 3-(5-chloro-8-quinolinyloxy)propyl, fluoro, 2,6-difluorophenyl, 4-methoxy-2-methylphenyl, or 2,4-dichlorophenyl.

### Claim 16 (depends on 1)

The compound of claim 1 wherein R4 is 10-(2-ethoxyphenyl).

### Claim 17 (depends on 1)

The compound of claim 1 which is a compound of Formula (II):
477
wherein p is 0, 1, 2, or 3; and R2, R3, R4, Ar, and q are as defined in claim 1; or a pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 1)

The compound of claim 1 which is a compound of Formula (III):
478
wherein R2 and q are as defined as in claim 1; R8 is H or C1-6alkyl, R9 is H,C1-6alkyl, C1-6alkyl S—, or halo, and R10 is C1-6alkyl or C3-8cycloalkyl; or a pharmaceutically acceptable salt thereof.

### Claim 19

The compound: (5aS*, 10bS*)-10-(2-ethoxyphenyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole, (5aS, 10bS)-10-(2-ethoxyphenyl)-1,2,3,4,5,5a, 6,10b-octahydroazepino[4,5-b]indole, (5aR, 10bR)-10-(2-ethoxyphenyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole, (5aS*, 10bS*)-10-(2-butoxyphenyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole, (5aS, 10bS)-10-(2-butoxyphenyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole, (5aR, 10bR)-10-(2-butoxyphenyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole, (5aS*, 10bS*)-10-[2-(cyclohexyloxy)phenyl]-1,2,3,4,5,5a, 6,10b-octahydroazepino[4,5-b]indole, (5aS*,10bS*)-10-[2-(cyclobutyloxy)phenyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole, (5aS*, 10bS*)-10-[2-(trifluoromethoxy)phenyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole, or (5aS*,10bS*)-10-(2-chlorophenyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole; or a pharmaceutically acceptable salt thereof.

### Claim 20 (depends on 1)

A pharmaceutical composition comprising a compound as described in claim 1 and a pharmaceutically acceptable carrier.

### Claim 21 (depends on 1)

A method of treating a disease or disorder of the central nervous system in a mammal comprising administering to the mammal a pharmaceutically effective amount of a compound as described in claim 1.

### Claim 22 (depends on 21)

The method of claim 21 wherein the disease or disorder is anxiety, depression, schizophrenia, epilepsy, migraine, Alzheimers disease, sleep disorders, obesity, a stress related disease, or withdrawal from drug abuse.

### Claim 23 (depends on 21)

The method of claim 21 wherein the disease or disorder is anxiety, depression, epilepsy, migraine, obesity, a stress related disease, and withdrawal from drug abuse.

### Claim 24

A compound of Formula (I):
479
wherein:
R1 is selected from the group consisting of hydrogen, C1-8alkyl, and C1-8hydrocarbyleneAr;
each R2, independently, is selected from the group consisting of C1-8alkyl, and OH;
R3 is hydrogen, C1-8alkyl, Ar, Het, R7C(═O)—, R7OC(═O)—, R5R6NC(═O)—, R7C(═S)—, R7SC(═O)—, R5R6NC(═S)—, R7SO2—, R5R6NSO2—, R7S(═O)—, R5R6NS(═O)—, RcC1-8hydrocarbylene—, or RcC1-8hydrocarbyleneC(═O)—;
each R4, independently, is selected from the group consisting of Ar, C1-8alkyl, ArO—, C1-8alkoxy, Het, halo, OH, CN, NO2, CF3, CF3O, NRaRb, N═CRaRb, R7S, C1-8hydrocarbyleneAr, and C1-8hydrocarbyleneORa;
each R5 and R6 is independently hydrogen, C1-8alkyl, C2-8alkenyl, C2-8alkynyl, haloC1-8alkyl, C3-8cycloalkenyl, Ar, or —C1-8hydrocarbyleneAr; or R5 and R6 together with the nitrogen to which they are attached form a pyrrolidino, piperidino, morpholino, or thiomorpholino ring;
each R7 is independently hydrogen, C1-8alkyl, C2-8alkenyl, C2-8alkynyl, haloC1-8alkyl, C3-8cycloalkenyl, Ar, or —C1-8hydrocarbyleneAr;
Ra and Rb, independently, are selected from the group consisting of hydrogen, C1-8alkyl, Ar, C1-3hydrocarbyleneAr, SO2Ar, SO2C1-4alkyl, (C3-8cycloalkyl)C1-8alkylene, and Het;
Rc is Ar, Het, R7CO2—, R7C(═O)—, R7OC(═O)—, R7O—, R7C1-8alkyleneO—, R7S—, R7C(═S)—, R7S(═O)—, R7S(═O)2—, R7SC(═O)—, R7C(═O)N(R7)—, R7C(═S)N(R7)—, R5R6N—, R5R6NC(═O)—, R5R6NC(═S)—, R5R6NS(═O)—, R5R6NSO2—, R7S(═O)N(R7)—, R7SO2N(R7)—, or R7N(R7)C(═O) N(R7)—;
each Ar is independently aryl or heteroaryl;
p is 0, 1, 2, 3, or 4; and
q is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
wherein any Ar of R1, R3-R7, Ra, Rb and Rc is optionally substituted with one or more substituents independently selected from halo, CN, NO2, ORc, methylenedioxy, ethylenedioxy, CF3, OCF3, SRe, SO2Re, NRfRg, CONRfRg, CORe, Re, and C1-8hydrocarbyleneRd;
each Rd is independently hydroxy, C1-8alkoxy, cyano, SRh, or C(═O)Rh;
each Re is independently selected from the group consisting of hydrogen, C1-8alkyl, Ar, C1-3hydrocarbyleneAr, SO2Ar, SO2C1-4alkyl, (C3-8cycloalkyl)C1-8alkylene, and Het; wherein any Ar of Re is optionally substituted with one or more substituents independently selected from halo, CN, NO2, ORd, methylenedioxy, ethylenedioxy, CF3, OCF3, SRf, SO2Rf, NRfRg, CONRfRg, CORf, Rf, and C1-8hydrocarbyleneRd;
each Rf and Rg, is independently selected from the group consisting of hydrogen, C1-8alkyl, Ar, C1-3hydrocarbyleneAr, SO2Ar, SO2C1-4alkyl, (C3-8cycloalkyl)C1-8alkylene, and Het; and
each Rh is independently hydrogen, C1-8alkyl, C2-8alkenyl, C2-8alkynyl, haloC1-8alkyl, C3-8cycloalkenyl, phenyl, or —C1-8hydrocarbylene(phenyl);
or a pharmaceutically acceptable salt thereof;
provided that when
(a) R1 is methyl; and
(b) R3 is hydrogen or —(CH2)3NR5R6, wherein R5 and R6 are each methyl;
then either
(i) p is not 0 and at least one R4 is Ar, ArO—, C1-8alkoyl, Het, halo, OH, CN, NO2, CF3, CF3O, NRaRb, N═CRaRb, R7S—, C1-8hydrocarbyleneAr, or C1-8hydrocarbyleneORa; or
(ii) q is not 0 and at least one R2 is OH.

### Claim 25 (depends on 24)

The compound of claim 24 wherein R1 is hydrogen.

### Claim 26 (depends on 24)

The compound of claim 24 wherein q is 2, 3, or 4.

### Claim 27 (depends on 24)

The compound of claim 24 wherein q is 1.

### Claim 28 (depends on 24)

The compound of claim 24 wherein q is 0.

### Claim 29 (depends on 24)

The compound of claim 24 wherein R3 is hydrogen, C1-8alkyl, R5R6NC(═O)CH2—, R7SC1-8alkylene, or aryloxy(CH2)2—.

### Claim 30 (depends on 24)

The compound of claim 24, wherein R3 is hydrogen.

### Claim 31 (depends on 24)

The compound of claim 24 wherein R3 is C1-8alkyl, R5R6NC(═O)CH2— or aryloxy(CH2)2—.

### Claim 32 (depends on 24)

The compound of claim 24 wherein R3 is: 2-(3-methoxyphenoxy)ethyl, 2-(3-nitrophenoxy)ethyl, 2-(3-isopropylphenoxy)ethyl, 2-(4-pyridyloxy)ethyl, 3-phenoxypropyl, 3-(3-chlorophenoxy)propyl, 3-(4-fluorophenoxy)propyl, 2-phenoxyethyl, N-(2,3-dimethylphenyl)amino-carbonylmethyl, N-(3-methylphenyl)aminocarbonylmethyl, N-(2-fluoro-4-methylphenyl)aminocarbonylmethyl, N-mesitylaminocarbonylmethyl, N-(4-methoxyphenyl)aminocarbonylmethyl, N-(phenyl)aminocarbonylmethyl, N-(4-fluorophenyl)aminocarbonylmcthyl, N-(3-nitrophenyl)aminocarbonylmethyl, N-(3-methoxyphenyl)aminocarbonylmethyl, N-(4-cyanophenyl)aminocarbonylmethyl, N-(3,5-dimethoxyphenyl)aminocarbonylmethyl, N-(2,4-dimethoxyphenyl)aminocarbonylmethyl, N-(3-chloro-4-fluorophenyl)aminocarbonylmethyl, 2-anilinoethyl, 1H-benzimidazol-2-ylmethyl, isobutoxycarbonylmethyl, carboxymethyl, N,N-dimethylaminocarbonylmethyl, aminocarbonylmethyl, 2-(phenylsulfinyl)ethyl, 2-(phenylsulfonyl)ethyl, 2-hydroxyethyl, 2-(4-chlorophenoxy)ethyl, 2-(4-fluorophenoxy)ethyl, 2-(phenylthio)ethyl, 2-aminoethyl, 2-(anilinocarbonylamino)-ethyl, 2-(benzoylamino)ethyl, 2-(phenylsulfonylamino)ethyl, N-(4-methoxyphenyl)aminocarbonylethyl, N-phenylaminocarbonylmethyl, N-(2-pyridyl)aminocarbonylmethyl, N-(4-methoxyphenyl)aminocarbonylmethyl, N-(2,3-dimethylphenyl)aminocarbonylmethyl, N-(5,6,7,8-tetrahydro-1-naphthalenyl)aminocarbonylmethyl, 3-ethylanilinocarbonylmethyl, 3-isopropylanilinocarbonylmethyl, N-(3-tert-butylphenyl)aminocarbonylmethyl, N-(1,3-benzothiazol-2-yl)aminocarbonylmethyl, N-(4-methyl-1,3-thiazol-2-yl)aminocarbonylmethyl, N-(5-methyl-1,3-thiazol-2-yl)aminocarbonylmethyl, N-(4-tert-butyl-1,3-thiazol-2-yl)aminocarbonylmethyl, N-(4-phenyl-1,3-thiazol-2-yl)aminocarbonylmethyl, 3-pbenylpropyl, 2-phenoxyethyl, 2-(4-chlorophenoxy)ethyl, 2-(4-fluorophenoxy)ethyl, 2-(5,7-dibromo-8-quinolinyloxy)ethyl, 2-(8-quinolinyloxy)ethyl, 2-(5-isoquinolinyloxy)ethyl, 2-(5-quinolinyloxy)ethyl, 2-(5,6,7,8-tetrahydro-1-naphthalenyloxy)ethyl, 2-(1,3-benzodioxol-5-yloxy)ethyl, 2-(1H-indol-4-yloxy)ethyl, 2-(5,6,7,8-tetrahydro-2-naphthalenyloxy)ethyl, 2-(7-quinolinyloxy)ethyl, 2-[(5,5-dimethyl-5,6,7,8-tetrahydronaphthalen-1-yl)oxy]ethyl, N-(3-chloro-2-methylphenyl)aminocarbonylmethyl, N-[2-methyl-3-(trifluoromethyl)phenyl]aminocarbonylmethyl, N-(5,6,7,8-tetrahydronaphthalen-1-yl)aminocarbonylmethyl, N-(4-methyl-1,3-thiazol-2-yl)aminocarbonylmethyl, N-(1,3-dihydro-2-benzofuran-4-yl)aminocarbonylmethyl, N-(4-methoxyphenyl)aminocarbonylmethyl, N-(3-pyridyl)aminocarbonylmethyl, N-(4-methyl-1,3-thiazol-2-yl)aminocarbonylmethyl, or 2-(5,6,7,8-tetrahydronaphthalen-1-yloxy)ethyl.

### Claim 33 (depends on 24)

The compound of claim 24 wherein p is 1, 2, or 3.

### Claim 34 (depends on 24)

The compound of claim 24 wherein p is 0.

### Claim 35 (depends on 24)

The compound of claim 24 wherein R4 is phenyl, optionally substituted at the 2-position of the phenyl.

### Claim 36 (depends on 24)

The compound of claim 24 wherein R4 is 2-ethoxyphenyl, or 2-chlorophenyl.

### Claim 37 (depends on 24)

The compound of claim 24 wherein R4 is aryl, substituted at the 10-position of formula (I).

### Claim 38 (depends on 24)

The compound of claim 24 wherein R4 is: 5-pyrimidinyl, 3,4-dimethoxyphenyl, 3,5-difluorophenyl, 4-n-butyloxyphenyl, 4-trifluoromethoxyphenyl, 3,4-dichlorophenyl, 2-naphthyl, 4-pyridinyl, bromo, benzhydrilideneamino, amino, N-(phenylsulfonyl)amino, phenoxy, 3-(phenoxy)propyl, 3-(2-naphthyloxy)propyl, 3-(1-naphthyloxy)propyl, 3-([1,1′-biphenyl]-4-yloxy)propyl, 3-(3-methoxyphonoxy)propyl, 3-(4-methoxyphenoxy)propyl, 3-(4-chlorophenoxy)propyl, 3-(3-chlorophenoxy)propyl, 3-(2-chlorophenoxy)propyl, 3-(2,4-dichlorophenoxy)propyl, 3-(2,5-dichlorophenoxy)propyl, 3-(4-fluorophenoxy)propyl, 3-(4-methylphenoxy)propyl, 3-(4-cyanophenoxy)propyl, 3-(pyridin-2-yloxy)propyl, 3-(2-bromophenoxy)propyl, 3-(2-iodophenoxy)propyl, 3-(2-ethylphenoxy)propyl, 3-(2-isopropylphenoxy)propyl, 3-(2-cyanophenoxy)propyl, 3-(pyridin-3yloxy)propyl, 3-(3-fluorophenoxy)propyl, 3-(3-bromophenoxy)propyl, 3-(3-iodophenoxy)propyl, 3-(3-isopropylphenoxy)propyl, 3-[3-(trifluoromethyl)phenoxy]propyl, 3-[3-(trifluoromethoxy)phenoxy]propyl, 3-(3-ethylphenoxy)propyl, 3-(3-tert-butylphenoxy)propyl, 3-(pyridin-4yloxy)propyl, 3-(4-methoxyphenoxy)propyl, 3-[4-(benzyloxy)phenoxy]propyl, 3-(4-bromophenoxy)propyl, 3-(4-iodophenoxy)propyl, 3-(4-ethylphenoxy)propyl, 3-(4-tert-butylphenoxy)propyl, 3-[4′-(bromo[1,1′-biphenyl]-4-yl)oxy]propyl, 3-(2,3-difluorophenoxy)propyl, 3-(2,4-dibromophenoxy)propyl, 3-(2,4-difluorophenoxy)propyl, 3-(2-methoxy-4-methylphenoxy)propyl, 3-(4-iodo-2-methylphenoxy)propyl, 3-(2,5-difluorophenoxy)propyl, 3-(2-chloro-5-methylphenoxy)propyl, 3-(2-isopropyl-5-methylphenoxy)propyl, 3-(2,6-difluorophenoxy)propyl, 3-(2,6-dichlorophenoxy)propyl, 3-(2,6-dimethylphenoxy)propyl, 3-(2-fluoro-6-methylphenoxy)propyl, 3-hydroxypropyl, 3-(2,3,6-trimethylphenoxy)propyl, 3-(mesityloxy)propyl, 3-(2,6-dibromo-4-fluorophenoxy)propyl, 3-(4-chloro-3-fluorophenoxy)propyl, 3-(4-chloro-3-methylphenoxy)propyl, 3-(3-chloro-4-fluorophenoxy)propyl, 3-(1,3-benzodioxol-5-yloxy)propyl, 3-(3,5-dichlorophenoxy)propyl, 3-(3,5-dimethylphenoxy)propyl, 3-(3,5-dimethoxyphenoxy)propyl, 3-(5,6,7,8-tetrahydro-1-naphthalenyloxy)propyl, 3-[(2,4-dichloro-1-naphthyl)oxy]propyl, 3-[4-methoxy-1-naphthyl)oxy]propyl, 3-[4-chloro-1-naphthyl)oxy]propyl, 3-[1,6-dibromo-2-naphthyl)oxy]propyl, 3-[1-bromo-2-naphthyl)oxy]propyl, 3-(2,3,4,5,6-pentafluorophenoxy)propyl, 3-(5-isoquinolinyloxy)propyl, 2-methyl-4-methoxyphenyl, 2-ethoxyphenyl, phenyl, phenoxy, 4-pyridinyl, 4-methoxyphenyl, 3,5-difluorophenyl, 3-[1,1′-biphenyl]-2-yloxypropyl, chloro, 2,6-difluorophenyl, bromo, 2-methylphenyl, 2-methoxyphenyl, 2-propoxyphenyl, 2-fluorophenyl, 2,4-dichlorophenyl, 3-(2,4-dibromophenoxy)propyl, 3-(5-chloro-8-quinolinyloxy)propyl, fluoro, 2,6-difluorophenyl, 4-methoxy-2-methylphenyl, or 2,4-dichlorophenyl.

### Claim 39 (depends on 24)

The compound of claim 24 wherein R4 is 10-(2-ethoxyphenyl).

### Claim 40 (depends on 24)

A pharmaceutical composition comprising a compound as described in claim 24 and a pharmaceutically acceptable carrier.

### Claim 41 (depends on 24)

A method of treating anxiety, depression, epilepsy, migraine, or obesity in a mammal comprising administering to the mammal a pharmaceutically effective amount of a compound as described in claim 24.

### Claim 42 (depends on 41)

The method of claim 41 wherein the disease or disorder is anxiety or depression.
